SMAD3 and breast carcinoma: Earlier studies have identified the downregulation of the TGF-β/Smad3 signaling pathway as a critical factor contributing to the inhibition of cell proliferation and the induction of cell cycle arrest in EA-treated MCF-7 breast cancer cells [68,69].